Do analysts recommend ALVR or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ALVR or APM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Aptorum Group N/A N/A -$1.36M N/A N/A

Is ALVR or APM more profitable?

Aptorum Group's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Aptorum Group N/A N/A N/A

Do analysts rate APM or CELU?

Celularity has a consensus price target of $6.00, suggesting a potential upside of 886.84%. Given Celularity's stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, APM or CELU?

Aptorum Group has higher earnings, but lower revenue than Celularity. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group N/A N/A -$1.36M N/A N/A Celularity $26.55M 0.66 -$91.72M -$3.33 N/A

Is APM or CELU more profitable?

Aptorum Group has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Celularity -345.45% N/A -77.94%

Do analysts rate VYNE or APM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, VYNE or APM?

Aptorum Group has lower revenue, but higher earnings than VYNE Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VYNE Therapeutics $454K 48.12 -$26.48M -$0.38 N/A Aptorum Group N/A N/A -$1.36M N/A N/A

Do analysts recommend LPCN or APM?

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 504.84%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, LPCN or APM?

Aptorum Group has lower revenue, but higher earnings than Lipocine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 10.32 -$9.63M -$1.88 N/A Aptorum Group N/A N/A -$1.36M N/A N/A

Does the media prefer LPCN or APM?

In the previous week, Lipocine and Lipocine both had 3 articles in the media. Lipocine's average media sentiment score of 0.39 beat Aptorum Group's score of 0.30 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MDCX or APM?

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 1,940.82%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medicus Pharma is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MDCX or APM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Aptorum Group N/A N/A -$1.36M N/A N/A

Is MDCX or APM more profitable?

Aptorum Group's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Aptorum Group N/A N/A N/A

Does the media prefer MDCX or APM?

In the previous week, Medicus Pharma and Medicus Pharma both had 3 articles in the media. Medicus Pharma's average media sentiment score of 1.43 beat Aptorum Group's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aptorum Group (APM) Competitors

$0.78 +0.00 (+0.23%)

As of 11:41 AM Eastern

Compare

APM vs. ALVR, CELU, VYNE, LPCN, and MDCX

Should you buy Aptorum Group stock or one of its competitors? MarketBeat compares Aptorum Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptorum Group include AlloVir (ALVR), Celularity (CELU), VYNE Therapeutics (VYNE), Lipocine (LPCN), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Aptorum Group compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Aptorum Group's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Aptorum Group	N/A	N/A	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A

In the previous week, Aptorum Group had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Aptorum Group and 0 mentions for AlloVir. Aptorum Group's average media sentiment score of 0.30 beat AlloVir's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Aptorum Group	Neutral

Summary

Aptorum Group beats AlloVir on 7 of the 9 factors compared between the two stocks.

How does Aptorum Group compare to Celularity?

Aptorum Group (NASDAQ:APM) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Aptorum Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Celularity has a consensus price target of $6.00, suggesting a potential upside of 886.84%. Given Celularity's stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aptorum Group has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Celularity	-345.45%	N/A	-77.94%

Aptorum Group has higher earnings, but lower revenue than Celularity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A
Celularity	$26.55M	0.66	-$91.72M	-$3.33	N/A

In the previous week, Aptorum Group had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat Aptorum Group's score of 0.30 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptorum Group	Neutral
Celularity	Very Positive

Summary

Celularity beats Aptorum Group on 7 of the 12 factors compared between the two stocks.

How does Aptorum Group compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aptorum Group has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Aptorum Group's return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Aptorum Group	N/A	N/A	N/A

In the previous week, Aptorum Group had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat Aptorum Group's score of 0.30 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VYNE Therapeutics	Very Positive
Aptorum Group	Neutral

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aptorum Group has lower revenue, but higher earnings than VYNE Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$454K	48.12	-$26.48M	-$0.38	N/A
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Summary

Aptorum Group beats VYNE Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aptorum Group compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Lipocine has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Aptorum Group has lower revenue, but higher earnings than Lipocine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.32	-$9.63M	-$1.88	N/A
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Lipocine and Lipocine both had 3 articles in the media. Lipocine's average media sentiment score of 0.39 beat Aptorum Group's score of 0.30 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aptorum Group has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Aptorum Group's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Aptorum Group	N/A	N/A	N/A

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 504.84%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lipocine beats Aptorum Group on 7 of the 12 factors compared between the two stocks.

How does Aptorum Group compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 1,940.82%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medicus Pharma is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

3.8% of Aptorum Group shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medicus Pharma and Medicus Pharma both had 3 articles in the media. Medicus Pharma's average media sentiment score of 1.43 beat Aptorum Group's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aptorum Group's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Aptorum Group	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A

Summary

Aptorum Group beats Medicus Pharma on 6 of the 10 factors compared between the two stocks.

Get Aptorum Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APM vs. The Competition

Export

Metric	Aptorum Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.92M	$3.04B	$6.76B	$12.51B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	N/A	19.59	25.78	24.73
Price / Sales	N/A	361.90	548.02	103.35
Price / Cash	N/A	56.85	29.14	36.96
Price / Book	0.36	4.27	10.84	6.52
Net Income	-$1.36M	$64.45M	$3.57B	$336.86M
7 Day Performance	-6.45%	3.08%	2.43%	1.31%
1 Month Performance	-24.76%	3.79%	0.76%	0.36%
1 Year Performance	-14.84%	34.58%	36.68%	30.89%

Aptorum Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APM Aptorum Group	0.6963 of 5 stars	$0.78 +0.2%	N/A	-20.4%	$4.92M	N/A	N/A	30
ALVR AlloVir	N/A	$4.37 +2.3%	N/A	+64.9%	$22.04M	N/A	N/A	110	Gap Up High Trading Volume
CELU Celularity	2.0843 of 5 stars	$0.74 +0.2%	$6.00 +713.0%	-67.2%	$21.37M	$26.55M	N/A	220	Positive News
VYNE VYNE Therapeutics	1.462 of 5 stars	$0.62 -1.4%	N/A	-54.4%	$21.01M	$454K	N/A	30	Positive News
LPCN Lipocine	3.841 of 5 stars	$2.46 +6.7%	$15.00 +511.0%	-24.3%	$20.23M	$1.98M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APM) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptorum Group (APM) Competitors

APM vs. ALVR, CELU, VYNE, LPCN, and MDCX

How does Aptorum Group compare to AlloVir?

Summary

How does Aptorum Group compare to Celularity?

Summary

How does Aptorum Group compare to VYNE Therapeutics?

Summary

How does Aptorum Group compare to Lipocine?

Summary

How does Aptorum Group compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptorum Group (APM) Competitors

APM vs. ALVR, CELU, VYNE, LPCN, and MDCX

How does Aptorum Group compare to AlloVir?

Do analysts recommend ALVR or APM?

Which has more volatility & risk, ALVR or APM?

Is ALVR or APM more profitable?

Do insiders and institutionals have more ownership in ALVR or APM?

Which has better valuation and earnings, ALVR or APM?

Does the media favor ALVR or APM?

Summary

How does Aptorum Group compare to Celularity?

Which has more risk and volatility, APM or CELU?

Do institutionals and insiders hold more shares of APM or CELU?

Do analysts rate APM or CELU?

Is APM or CELU more profitable?

Which has better earnings & valuation, APM or CELU?

Does the media prefer APM or CELU?

Summary

How does Aptorum Group compare to VYNE Therapeutics?

Do analysts rate VYNE or APM?

Is VYNE or APM more profitable?

Does the media prefer VYNE or APM?

Do institutionals and insiders have more ownership in VYNE or APM?

Which has stronger earnings and valuation, VYNE or APM?

Which has more risk and volatility, VYNE or APM?

Summary

How does Aptorum Group compare to Lipocine?

Which has more risk and volatility, LPCN or APM?

Which has better earnings & valuation, LPCN or APM?

Do insiders and institutionals believe in LPCN or APM?

Does the media prefer LPCN or APM?

Is LPCN or APM more profitable?

Do analysts recommend LPCN or APM?

Summary

How does Aptorum Group compare to Medicus Pharma?

Do analysts recommend MDCX or APM?

Which has more risk and volatility, MDCX or APM?

Do insiders and institutionals believe in MDCX or APM?

Does the media prefer MDCX or APM?

Is MDCX or APM more profitable?

Which has higher valuation & earnings, MDCX or APM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM vs. The Competition

Aptorum Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools